Sacubitril/valsartan: An antiarrhythmic drug? Article

Full Text via DOI: 10.1111/jce.15670 Web of Science: 000862973100001

Cited authors

  • Huang E, Bernard ML, Hiltbold AE, Khatib S, Polin GM, Rogers PA, Dominic P, Morin DP


  • Introduction Heart failure (HF) is a major cause of morbidity and mortality, with nearly half of all HF-related deaths resulting from sudden cardiac death (SCD), most often from an arrhythmic event. The pathophysiologic changes that occur in response to the hemodynamic stress of HF may lead to increased arrhythmogenesis. Theoretically, medications that block these arrhythmogenic substrates would decrease the risk of SCD. The combined angiotensin receptor and neprilysin inhibitor (ARNi; tradename Entresto) is the newest commercially available medication for the treatment of heart failure. Methods and Results We reviewed and synthesized the available literature regarding sacubitril/valsartan and its effects on cardiac rhythm. ARNi has been shown to decrease cardiovascular mortality and hospitalization in patients with HF with reduced ejection fraction (HFrEF). Emerging evidence suggests that ARNi also may play a role in reducing arrhythmogenesis and thereby SCD. Conclusion This review summarizes the current data regarding this ARNi and its potential antiarrhythmic effects.

Publication date

  • 2022

International Standard Serial Number (ISSN)

  • 1045-3873

Number of pages

  • 7